 WARMER, Penn., Sept. 28, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus HBV infection, as well as therapies to treat coronaviruses including COVID-19, today announced that the Company will participate in the following October investor conferences: 